MedTrace Logo

Use of Allogenic Platelet Lysate in Peripheral Arterial Disease (PAD)

NCT03297814 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2019-07-24

No results posted yet for this study

Summary

Allogenic platelet lysate will be injected in the gastrocnemius of patients with peripheral arterial disease (PAD)

Conditions

  • Peripheral Arterial Disease

Interventions

BIOLOGICAL

Platelet lysate

Intramuscular injection of platelet lysate

BIOLOGICAL

Placebo

intramuscular injection of normal saline

Sponsors & Collaborators

  • Sophia Al-Adwan

    lead OTHER

Principal Investigators

  • Abdalla Awidi, MD · Cell Therapy Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-18
Primary Completion
2020-03-31
Completion
2020-05-31

Countries

  • Jordan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03297814 on ClinicalTrials.gov